The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of ...

In this double-blind trial, we randomly assigned 5988 patients with class II–IV heart failure and an ejection fraction of more than 40% to receive empagliflozin (10 mg once daily) or placebo ...

This study from Kerman University of Medical Sciences have that empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) ...

Empagliflozin users had 741 events compared to 712 in the DPP4i group, corresponding to a non-significant HR of 1.04. For DR ...

SAN DIEGO — The significant kidney and cardiovascular benefits people with chronic kidney disease (CKD) show over 2 years of treatment with empagliflozin begin to subside within about a year ...

Compared with DPP4i, empagliflozin was associated with a lower risk of kidney- and cardiovascular-related outcomes in T2DM patients. Empagliflozin was found to significantly reduce the risk for ...

LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo. 50% percent of ...

In keeping with current guidelines, either empagliflozin or dapagliflozin can be used for preventing AKI and CKD in patients with type 2 diabetes. Empagliflozin and dapagliflozin are equally ...

Citation: SGLT2 inhibitor empagliflozin is shown to be safe and effective for treating patients who have suffered a heart attack (2024, September 2) retrieved 23 May 2025 from https ...